What implementation takes

Why implementation is hard

Some of the biggest barriers to lung cancer screening aren’t clinical—they’re systemic.

Dr. Scott Tackett

President & CEO

When we understand those systems, we can design solutions that work within them—and improve them.

Early cancer detection requires more than strong science and evidence. It requires solutions that fit real-world healthcare delivery and consistently reach everyone—not just the few.

Economics, social norms, governance, accessibility, availability, and affordability all shape whether evidence becomes better outcomes.

Improving cancer screening starts by understanding the system—and designing prevention around the people it’s meant to serve.

Originally shared on LinkedIn

Join the conversation and see how others have responded.

AIR-DS is a UKCA marked in vitro diagnostic medical device, developed in accordance with IEC 62304 and under an ISO 13485 certified quality management system. In the US, a CLIA certified laboratory will offer a laboratory developed test (LDT) with AIR-DS Lung Test. It has not been cleared or approved by the FDA. Information on this website is provided for educational and informational purposes and should not be interpreted as medical advice.

© 2026 Sierra Medical Ltd. trading as AIRA Sciences  ·  info@airasciences.com

© 2026 Sierra Medical Ltd. trading as AIRA Sciences  ·  info@airasciences.com

Privacy · Terms

Privacy · Terms